» Articles » PMID: 31602527

Ocular Abnormalities in Beta Thalassemia Patients: Prevalence, Impact, and Management Strategies

Overview
Journal Int Ophthalmol
Specialty Ophthalmology
Date 2019 Oct 12
PMID 31602527
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Beta thalassemia (β-thalassemia) is a hereditary disease caused by defective globin synthesis and can be classified into three categories of minor (β-TMi), intermedia (β-TI), and major (β-TM) thalassemia. The aim of our study is to investigate the effects of β-thalassemia and its treatment methods on different parts of the eye and how early-diagnostic methods of ocular complications in this disorder would prevent further ocular complications in these patients by immediate treatment and diet change.

Methods: We developed a search strategy using a combination of the words Beta thalassemia, Ocular abnormalities, Iron overload, chelation therapy to identify all articles from PubMed, Web of Science, Scopus, and Google Scholar up to December 2018. To find more articles and to ensure that databases were thoroughly searched, the reference lists of selected articles were also reviewed.

Results: Complications such as retinopathy, crystalline lens opacification, color vision deficiency, nyctalopia, depressed visual field, reduced visual acuity, reduced contrast sensitivity, amplitude reduction in a-wave and b-wave in Electroretinography (ERG), and decrease in the Arden ratio in Electrooculography (EOG) have all been reported in β-thalassemia patients undergoing chelation therapy.

Conclusion: Ocular problems due to β-thalassemia may be a result of anemia, iron overload in the body tissue, side effects of iron chelators, and the complications of orbital bone marrow expansion.

Citing Articles

Ocular biometry, anterior chamber morphometry, and their relationship with serum ferritin levels in children with beta thalassemia major.

Simdivar G, Kurumoglu Incekalan T, Tuncel D Ther Adv Ophthalmol. 2023; 15:25158414231165824.

PMID: 37113304 PMC: 10126650. DOI: 10.1177/25158414231165824.


Do We Store Packed Red Blood Cells under "Quasi-Diabetic" Conditions?.

Livshits L, Barshtein G, Arbell D, Gural A, Levin C, Guizouarn H Biomolecules. 2021; 11(7).

PMID: 34356616 PMC: 8301930. DOI: 10.3390/biom11070992.


Ocular findings in patients with transfusion-dependent β-thalassemia in southern Iran.

Haghpanah S, Zekavat O, Bordbar M, Karimi M, Zareifar S, Safaei S BMC Ophthalmol. 2020; 20(1):376.

PMID: 32962679 PMC: 7510146. DOI: 10.1186/s12886-020-01647-y.

References
1.
Simon S, Athanasiov P, Jain R, Raymond G, Gilhotra J . Desferrioxamine-related ocular toxicity: a case report. Indian J Ophthalmol. 2012; 60(4):315-7. PMC: 3442469. DOI: 10.4103/0301-4738.98714. View

2.
Gelman R, Kiss S, Tsang S . Multimodal imaging in a case of deferoxamine-induced maculopathy. Retin Cases Brief Rep. 2014; 8(4):306-9. PMC: 4221805. DOI: 10.1097/ICB.0000000000000059. View

3.
Liaska A, Petrou P, Georgakopoulos C, Diamanti R, Papaconstantinou D, Kanakis M . β-Thalassemia and ocular implications: a systematic review. BMC Ophthalmol. 2016; 16:102. PMC: 4938965. DOI: 10.1186/s12886-016-0285-2. View

4.
Olivieri N, Buncic J, Chew E, Gallant T, Harrison R, Keenan N . Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med. 1986; 314(14):869-73. DOI: 10.1056/NEJM198604033141402. View

5.
Marciani M, Cianciulli P, Stefani N, Stefanini F, Peroni L, Sabbadini M . Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function. Haematologica. 1991; 76(2):131-4. View